-
Vildagliptin
- indication:Used to reduce hyperglycemia in type 2 diabetes mellitus.
- pharmacologypharmacology:
- mechanism: Vildagliptin inhibits the inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta cells. Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP and the degradation of GLP-1.
- toxicity:
- absorprion: Rapidly absorbed following oral administration with an oral bioavailability of greater than 90%.
- halflife: The elimination half-life is approximately 90 minutes.
- roouteelimination:
- volumedistribution:
- clearance: